公开(公告)号：US10294299B2

公开(公告)日：2019-05-21

申请号：US15513395

申请日：2017-01-20

申请人： MabQuest SA

发明人： Giuseppe Pantaleo ,  Craig Fenwick

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P31/18 ,  A61P35/00 ,  A61K39/00

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.

公开(公告)号：US11214617B2

公开(公告)日：2022-01-04

申请号：US15981983

申请日：2018-05-17

申请人： MabQuest SA

发明人： Giuseppe Pantaleo ,  Craig Fenwick

IPC分类号： C07K16/28 ,  A61K39/00 ,  C07K16/10 ,  G01N33/68

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.

公开(公告)号：US20220169733A1

公开(公告)日：2022-06-02

申请号：US17485752

申请日：2021-09-27

申请人： MabQuest SA

发明人： Giuseppe Pantaleo ,  Craig Fenwick

IPC分类号： C07K16/28 ,  C07K16/10 ,  G01N33/68

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.

公开(公告)号：US20220259315A1

公开(公告)日：2022-08-18

申请号：US17567251

申请日：2022-01-03

申请人： MabQuest SA

发明人： Giuseppe Pantaleo ,  Craig Fenwick

IPC分类号： C07K16/28 ,  C07K16/10 ,  G01N33/68

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.

公开(公告)号：US20190106493A1

公开(公告)日：2019-04-11

申请号：US15981977

申请日：2018-05-17

申请人： MabQuest SA

发明人： Giuseppe Pantaleo ,  Craig Fenwick

IPC分类号： C07K16/28 ,  C07K16/10 ,  G01N33/68

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.

公开(公告)号：US20190062431A1

公开(公告)日：2019-02-28

申请号：US15981983

申请日：2018-05-17

申请人： MabQuest SA

发明人： Giuseppe Pantaleo ,  Craig Fenwick

IPC分类号： C07K16/28 ,  G01N33/68 ,  C07K16/10

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.

公开(公告)号：US20180265582A1

公开(公告)日：2018-09-20

申请号：US15513395

申请日：2017-01-20

申请人： MabQuest SA

发明人： Giuseppe Pantaleo ,  Craig Fenwick

IPC分类号： C07K16/28 ,  A61P31/18 ,  A61P35/00

CPC分类号： C07K16/2803 ,  A61K39/39541 ,  A61K39/39558 ,  A61K2039/507 ,  A61P31/18 ,  A61P35/00 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/75 ,  C07K2317/76

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.

公开(公告)号：US20230034677A1

公开(公告)日：2023-02-02

申请号：US17778617

申请日：2020-11-20

申请人： INSERM (Institut National de la Santé et la Recherche (Médicale) ,  Assistance Publique-Hôpitaux de Paris (APHP) ,  Université Paris-Est Créteil val de Marne ,  Baylor Research Institutue ,  Mabquest

发明人： Yves LEVY ,  Giuseppe PANTALEO ,  Craig FENWICK ,  Sandra ZURAWSKI ,  Gérard ZURAWSKI ,  Nabila SEDDIKI

IPC分类号： C07K14/54 ,  C07K14/715 ,  A61P35/00

摘要： The inventors now provide novel IL-15/IL-15 receptor alpha (IL-15Rα) fusion proteins. Furthermore, as a complement to anti-PD-1 therapy, the inventors developed a series of anti-PD-1/IL-15/IL-15 receptor alpha (IL-15Rα) immunocytokines that are able to simultaneously target multiple steps in the immune activation process. The development of said immunocytokines provides the potential benefits associated with anti-PD-1 antibodies and IL-15 administered individually with several distinct advantages. These include a significantly extended in vivo half-life relative to the IL-15 therapy, administration of a pre-formed IL-15/IL-15Rα complex that would preclude the need for IL-15Rα trans-presentation, high activity leading to a low target therapeutic dose and targeted delivery of IL-15 to regions with high PD-1 cells that will limit off-target adverse events.

公开(公告)号：US11130807B2

公开(公告)日：2021-09-28

申请号：US15981977

申请日：2018-05-17

申请人： MabQuest SA

发明人： Giuseppe Pantaleo ,  Craig Fenwick

IPC分类号： C07K16/28 ,  A61K39/00 ,  C07K16/10 ,  G01N33/68

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.

公开(公告)号：US09982053B2

公开(公告)日：2018-05-29

申请号：US15329760

申请日：2015-08-05

申请人： MabQuest SA

发明人： Giuseppe Pantaleo ,  Craig Fenwick

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/10 ,  G01N33/68 ,  A61K39/00

CPC分类号： C07K16/2818 ,  A61K2039/507 ,  C07K16/1063 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6893

摘要： This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity.